Participants 157 192 6
advanced colorectal cancer patients
Participants 615 694 7
advanced colorectal cancer (ACC) patients treated in the phase III CAIRO2 study
Participants 718 780 5
Seven hundred and fifty five previously untreated ACC patients
Participants 1116 1168 4
Seven hundred and thirty two patients were evaluable
